

Lund July 15, 2026

EQL Pharma AB (publ)

Org.nr. 556713-3425

Mellozzan® (melatonin) approved in Kazakhstan

EQL Pharma's key product Mellozzan® (tablets) has been approved for sale in Kazakhstan.

Approval has been obtained by EQL's regional partner, Abdi Ibrahim.

The approval currently covers the 3 mg strength. The Marketing Authorisation for the 5 mg strength is expected in December 2026. The launch of both strengths is expected in the fiscal year 2027/28.

About Mellozzan®

Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.

About EQL

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 47 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2026 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.

About Abdi Ibrahim

Turkish pharmaceutical industry leader Abdi İbrahim's journey of healing began in a small pharmacy store established in 1912 by the Pharmacist Abdi İbrahim Bey in Küçükmustafapaşa, Istanbul. Today, in addition to its partnerships with more than 30 licensing firms across the globe, Abdi İbrahim develops its own products and boasts the largest portfolio in the industry, with 255 brands and over 530 products. With its powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has held a leading position in the Turkish pharmaceutical industry since 2002. Today, Abdi İbrahim has subsidiaries operating in 19 countries outside Türkiye, exports to more than 70 countries from the European Union to Canada, North Africa to Asia, and generates the highest employment rate in the Turkish pharmaceutical industry with 6.000 qualified employees.

Abdi İbrahim's Esenyurt Production Complex in Istanbul houses the company's R&D Centre, Chemical Products Production Facility, Türkiye's largest biotechnological manufacturing facility AbdiBio, Hormone Production Facility, Sterile Ophthalmology & Sterile Inhalation Production Facility, and Chemical, Oncology, and Sterile Supplementary Production Facility. Abdi İbrahim also has R&D centers and production facilities in Kazakhstan and Algeria.

Press Release

Lund July 15, 2026

EQL Pharma AB (publ)

Org.nr. 556713-3425

www.abdiibrahim.com.tr

For more information contact:

Axel Schörling

CEO & President, EQL Pharma AB (publ)

Tel.: +46 (0) 76 317 90 60

email: axel.schorling@eqlpharma.com

Web: www.eqlpharma.com

EQL PHARMA

EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 47 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2026 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.